Taysha Gene Therapies Inc
NASDAQ:TSHA

Watchlist Manager
Taysha Gene Therapies Inc Logo
Taysha Gene Therapies Inc
NASDAQ:TSHA
Watchlist
Price: 1.72 USD Market Closed
Market Cap: 352.6m USD

P/FCFE
Price to FCFE

-4.1
Current
-3.4
Median
24.9
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-4.1
=
Market Cap
352.5m USD
/
FCFE
-86.9m USD
 
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
Average P/FCFE: 31.4
Negative Multiple: -4.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 097 600.1
US
Abbvie Inc
NYSE:ABBV
17
US
Amgen Inc
NASDAQ:AMGN
52.5
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -137.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -443
AU
CSL Ltd
ASX:CSL
54
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.9
NL
argenx SE
XBRU:ARGX
Negative Multiple: -107.3

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A